Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics Inc (PLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 869,091
  • Shares Outstanding, K 59,896
  • Annual Sales, $ 9,690 K
  • Annual Income, $ -123,320 K
  • 60-Month Beta 1.12
  • Price/Sales 89.74
  • Price/Cash Flow N/A
  • Price/Book 1.72
Trade PLRX with:

Options Overview Details

View History
  • Implied Volatility 61.30% ( +3.57%)
  • Historical Volatility 49.54%
  • IV Percentile 29%
  • IV Rank 16.70%
  • IV High 116.80% on 01/17/23
  • IV Low 50.18% on 06/21/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 30
  • Volume Avg (30-Day) 141
  • Put/Call OI Ratio 1.22
  • Today's Open Interest 5,449
  • Open Int (30-Day) 3,379

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.77
  • Number of Estimates 6
  • High Estimate -0.71
  • Low Estimate -0.84
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -6.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.60 +16.70%
on 11/13/23
16.08 -8.52%
on 11/10/23
-0.98 (-6.25%)
since 11/07/23
3-Month
12.60 +16.70%
on 11/13/23
18.03 -18.41%
on 10/06/23
-2.20 (-13.01%)
since 09/07/23
52-Week
12.60 +16.70%
on 11/13/23
36.64 -59.85%
on 01/27/23
-3.26 (-18.14%)
since 12/07/22

Most Recent Stories

More News
Why Shares of Pliant Therapeutics Are Rising Tuesday

The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.

PLRX : 14.72 (+1.45%)
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

PLRX : 14.72 (+1.45%)
BOLT : 0.9201 (-0.01%)
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 10.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CRDF : 1.2900 (-3.73%)
PLRX : 14.72 (+1.45%)
3 Low-Rated POWR Stocks to Sell Immediately

The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year. Hence, it could be wise...

KRBP : 0.2188 (+17.63%)
LOCL : 3.26 (-6.86%)
PLRX : 14.72 (+1.45%)
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

PLRX : 14.72 (+1.45%)
CRMD : 3.56 (-1.39%)
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 2.18 (unch)
PLRX : 14.72 (+1.45%)
Techne (TECH) Q2 Earnings and Revenues Miss Estimates

Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TECH : 67.95 (+2.89%)
PLRX : 14.72 (+1.45%)
Why Pliant Therapeutics Stock Is Skyrocketing This Week

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

PLRX : 14.72 (+1.45%)
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

CPRX : 14.24 (+1.64%)
BLUE : 4.77 (-1.24%)
AXLA : 0.9400 (+3.24%)
PLRX : 14.72 (+1.45%)
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

ADCT : 1.0800 (+0.93%)
RCUS : 15.63 (-1.14%)
ETON : 3.63 (+1.97%)
PLRX : 14.72 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO,...

See More

Key Turning Points

3rd Resistance Point 15.48
2nd Resistance Point 15.11
1st Resistance Point 14.81
Last Price 14.72
1st Support Level 14.14
2nd Support Level 13.77
3rd Support Level 13.47

See More

52-Week High 36.64
Fibonacci 61.8% 27.46
Fibonacci 50% 24.62
Fibonacci 38.2% 21.79
Last Price 14.72
52-Week Low 12.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar